- Home
- About
- Find staff
- Åsa Jellvert
Åsa Jellvert
Affiliated to Research
Department of Oncology-
Effect of docetaxel added to bicalutamide in Hormone-Naive non-metastatic prostate cancer with rising PSA, a randomized clinical trial
(SPCG-14)
Andreas Josefsson, Åsa Jellvert, Erik Holmberg, K. Brasso, P. M. Petersen, S. Aaltomaa, M. Luukkaa, P. Verhagen, R. de Wit, G. Ahlgren, O. Andren, E. Castellanos, M. Seke, A. Widmark, Jan-Erik Damber
Acta Oncologica - 2023 -
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2
Study
M. Lindskog, A. Laurell, A. Kjellman, B. Melichar, P. M. Rey, H. Zielinski, F. Villacampa, P. Bigot, B. Zoltan, O. Parikh, D. V. Alba, Åsa Jellvert, T. Flasko, E. Gallardo, M. J. R. Caparros, G. Purkalne, P. Suenaert, A. Karlsson-Parra, B. Ljungberg
European Urology Open Science - 2022 -
Aspects of Chemotherapy in Prostate
Cancer
Åsa Jellvert
2021 -
Castration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate
cancer.
Åsa Jellvert, Daniel Åhs, Josefin Olausson, Ingela Franck Lissbrant, Jan-Erik Damber, Karin Welén
Acta oncologica (Stockholm, Sweden) - 2018 -
Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate
cancer.
Åsa Jellvert, Ingela Franck-Lissbrant, Maliha Edgren, Elisabeth Ovferholm, Karin Braide, Ann-Marie Ekelund Olvenmark, Jon Kindblom, Per Albertsson, Bo Lennernäs
Experimental and therapeutic medicine - 2011